Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Wuhan YZY Biopharma Co., Ltd. Class H ( (HK:2496) ) has shared an update.
Wuhan YZY Biopharma Co., Ltd. has announced the appointment of Dr. Hu Liaoyuan as its new Chief Scientific Officer. Dr. Hu brings over thirty years of R&D and management experience to the company, having previously held significant roles at Lexicon Pharmaceuticals, Eli Lilly, and Amgen. His appointment is expected to enhance the company’s R&D capabilities and strategic development in the biopharmaceutical sector.
More about Wuhan YZY Biopharma Co., Ltd. Class H
Wuhan YZY Biopharma Co., Ltd. operates in the biopharmaceutical industry, focusing on the discovery, development, and commercialization of antibodies. The company is based in the People’s Republic of China and is listed on the Hong Kong Stock Exchange.
YTD Price Performance: -43.84%
Average Trading Volume: 3,180
Technical Sentiment Signal: Strong Buy
Find detailed analytics on 2496 stock on TipRanks’ Stock Analysis page.